BTK and cancer: With the rapid clinical development of novel agents of bispecific antibodies [76–78], antibody-drug conjugates [79, 80], immune checkpoint blockers [81–83], and CAR-T for cancer immunotherapies [84–87], combinations of BTK inhibitors with novel agents may overcome acquired resistance in refractory B cell malignancies [88].